PEPTIDE COMPARISON

Semax vs DSIP

Limited neurologic research compared with a very small historical sleep-peptide record.

QUICK ANSWER

Semax vs DSIP: the main difference.

Semax has more recent human research than DSIP, but neither has a U.S.-approved clinical program. Their marketed cognitive and sleep claims answer different questions and remain weakly supported.

Decision field	Semax	DSIP
Human research	Limited regional neurologic studies	Tiny historical sleep studies
Primary research	Stroke and neurotrophic signaling	Sleep physiology and stress response
FDA status	Not approved; compounding concerns	Not approved
Main uncertainty	Independent replication and product quality	Identity, mechanism, and modern efficacy
Evidence confidence	Low	Very low

SOURCES

Semax vs DSIP sources.

Human trial / 2018Semax in acute ischemic strokePubMed FDA / 2026Bulk substances that may present significant safety risksU.S. FDA WADA / 20262026 Prohibited ListWorld Anti-Doping Agency Human trial / 1981Double-blind crossover study of DSIP in healthy volunteersPubMed Review / 1983Delta sleep-inducing peptide: human studies reviewPubMed Government / 2023Compounding pharmacy plea involving unlawful unapproved drug distributionU.S. Department of Justice

Semax vs DSIP: the main difference.

Semax vs DSIP sources.

Questions related to Semax vs DSIP.

Compare the next decision.